US PHARMACEUTICAL company Eisai has announced it has bought the global marketing and distribution rights for chronic weight management treatment Belviq and Belviq XR (lorcaserin HCl) from Arena Pharmaceuticals.
Lorcaserin is a serotonin agonist targeting receptors in the brain that generate a sense of satiety.
The agreement will see Arena able to earn $26m in potential and regulatory milestones, including $25 million upon global net sales reaching $250 million in any 12 month period.
The above article was sent to subscribers in Pharmacy Daily's issue from 06 Jan 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Jan 17
